http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022152156-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bab51dbb81468c1c6978289aacc6d60a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate | 2021-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eacf4e5658695caea54a35b1da91769a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8a4d3f0781e28c8e2e486d2b427fa2f |
| publicationDate | 2022-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022152156-A1 |
| titleOfInvention | Method of using pegylated interferon-alpha |
| abstract | A method of treating a myeloid neoplasm in a subject, the method comprising administering to a subject in need thereof a 50 to 500 μg dose of a pegylated interferon-α once every 2 to 8 weeks, the pegylated interferon-α being a conjugate of formula I:in whicheach of R1, R2, R3, R4, and R5, independently, is H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, heteraryl, C3-8 cycloalkyl, or C3-8 heterocycloalkyl;each of A1 and A2, independently, is a polymer moiety;each of G1, G2, and G3, independently, is a bond or a linking functional group;P is an interferon-α moiety;m is 0 or an integer of 1-10; andn is an integer of 1-10;wherein the subject has a complete molecular response, the complete molecular response including a JAK2617F allele burden below 1%. |
| priorityDate | 2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.